What sector does Boston Scientific belong to?

Boston Scientific operates in the Health Care sector, specifically the Health Care Equipment industry, and is listed on the US markets.

What is the current share price of BSX?

As of the latest available quote, BSX traded at $42.98. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of BSX?

Boston Scientific has a price-to-earnings (P/E) ratio of about 17.40. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of BSX?

The market capitalisation of Boston Scientific is approximately $64.07B.

Is Boston Scientific profitable?

For its latest reported financial year, Boston Scientific recorded a net profit margin of about 14.41%.

Does BSX pay a dividend?

Boston Scientific does not currently show a dividend yield in our data.

What is the return on equity (ROE) of BSX?

Boston Scientific has a return on equity (ROE) of about 11.60%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of BSX?

Over the past 52 weeks, BSX has traded between a low of $42.20 and a high of $105.65.

Boston Scientific

BSX US Health Care Health Care Equipment

S&P 500

$42.98

-0.28%

Delayed · cached 15 min

Fair value analysis

BSX

Boston Scientific

$42.98

Close used for this calculation

$44.08Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

64/100

Profitability21/25

Returns10/25

Balance Sheet23/25

Efficiency10/25

Growth14/25

Good

Quality radar

Consensus fair value

$44.08

Near FV

▲ +2.6% against the close used

Model range $23.69 – $60.14

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$23.69Fair value$44.08Bull$60.14

FairClose

52-week traded range

52W low $42.6352W high $104.98

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Boston Scientific closed at $42.98, 2.5% below the consensus fair value of $44.08 drawn from 8 valuation models.

Financial DNA score 64/100 — Good. P/E of 22.2x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$48.71

+13.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$27.18

-36.8%

√(22.5 × EPS × BVPS)

EPS=1.94, BVPS=16.92 · outside Graham range (P/E 22.2, P/B 2.5) — asset-light, treat as a rough floor

P/E Fair Value

$38.80

-9.7%

EPS × 20x (sector P/E)

EPS=1.94, Sector P/E=20x

Peter Lynch (PEG)

$56.63

+31.8%

EPS × Growth% (PEG = 1 is fair)

EPS=1.94, g=29.2%

EV/EBITDA

$60.14

+39.9%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=4.98B

Book Value (P/B)

$23.69

-44.9%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=16.92, ROE=11.6%, g=6%, r=10%

Reverse DCF

$42.98

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 8.5% | Historical: 29.2%

Margin of Safety

$28.67

-33.3%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=38.23, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer